Jade Biosciences (JBIO) Price & Analysis

Compare

163 Followers

JBIO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$6.57 - $105.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)87.45K

Market Cap

$264.93M

Enterprise Value$63.88M

Total Cash (Recent Filing)$220.94M

Total Debt (Recent Filing)$792.00K

Price to Earnings (P/E)―

Beta0.43

Next Earnings

Nov 17, 2025

EPS Estimate

-0.55

Last Dividend Ex-Date

Apr 29, 2025

Dividend Yield29.56%

Share Statistics

EPS (TTM)-0.86

Shares Outstanding32,626,730

10 Day Avg. Volume79,889

30 Day Avg. Volume87,454

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.24

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-281.41

Enterprise Value/Ebitda-1.19

Forecast

1Y Price Target

$17.00

Price Target Upside110.92% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Drug PotencyJADE-001 is an anti-APRIL mAb with significantly greater potency and a longer dosing interval, offering an optimal benefit-risk profile for chronic therapy.

Leadership And ExpertiseJade Biosciences is led by a world-class team that previously sold an IgAN portfolio to Novartis for a significant amount, indicating strong leadership and expertise.

Market PotentialJADE-001 is expected to emerge as the optimal disease-modifying therapy and could capture a significant share of a multibillion-dollar market.

Bears Say

Competitive LandscapeUpdated preclinical data for JADE101 shows an impressive half-life of 27-33 days for subcutaneous dosing, surpassing competitors and potentially leading to greater IgA reductions.

Development TimelineThe Phase Ia trial is on track to initiate soon, with data expected to provide key insights into JADE101's performance.

Infection RiskA pure anti-APRIL approach like JADE-001 avoids the theoretical infection risk associated with unnecessary depletion of B-cells, potentially offering an optimal benefit-risk profile.

Jade Biosciences News

Jade Biosciences announces first cohort dosed in Phase 1 trial of JADE101

Jade Biosciences (JBIO) has dosed the first cohort of participants in a Phase 1 healthy volunteer trial of...

24d ago

JBIO

Jade Biosciences’ Chief Medical Officer Departs

Jade Biosciences ( ($JBIO) ) has provided an announcement. On September 9, 2025, Hetal Kocinsky, M.D. departed from...

17d ago

JBIO

Jade Biosciences Reports Q2 2025 Financial Results

Jade Biosciences, Inc. ( ($JBIO) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

JBIO

Jade Biosciences Signs Agreement with Patheon Biologics

An update from Jade Biosciences ( ($JBIO) ) is now available. On June 26, 2025, Jade Biosciences entered...

3M ago

JBIO

Jade Biosciences appoints Dahms as Chief Financial Officer

Jade Biosciences (JBIO) announced the appointment of Brad Dahms as Chief Financial Officer, CFO. Dahms was most recently...

3M ago

JBIO

Jade Biosciences upgraded to Buy from Neutral at Guggenheim

Guggenheim analyst Vamil Divan upgraded Jade Biosciences (JBIO) to Buy from Neutral with a $14 price target Published...

3M ago

JBIO

Jade Biosciences presents JADE101 preclinical data at ERA Congress

Jade Biosciences (JBIO) announced a detailed preclinical characterization of JADE101, its anti-A Proliferation-Inducing Ligand monoclonal antibody, in development...

4M ago

JBIO

Is AVTE a Buy, Before Earnings?

Aerovate Therapeutics, Inc. (AVTE) is scheduled to report 1st quarter earnings on 05/19/2025. Regarding Q1 estimates, Wall Street...

4M ago

JBIO

Promising Future for Jade Biosciences: Buy Rating Backed by Innovative JADE101 and Experienced Leadership

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on JBIO stock, giving a Buy rating...

4M ago

JBIO

Jade Biosciences Updates Corporate Presentation

Jade Biosciences ( ($JBIO) ) just unveiled an announcement. Jade Biosciences released its unaudited financial statements for the...

4M ago

JBIO

JBIO FAQ

What was Jade Biosciences’s price range in the past 12 months?

Jade Biosciences lowest stock price was $6.57 and its highest was $105.00 in the past 12 months.

What is Jade Biosciences’s market cap?

Jade Biosciences’s market cap is $264.93M.

When is Jade Biosciences’s upcoming earnings report date?

Jade Biosciences’s upcoming earnings report date is Nov 17, 2025 which is in 52 days.

How were Jade Biosciences’s earnings last quarter?

Jade Biosciences released its earnings results on Aug 13, 2025. The company reported -$0.86 earnings per share for the quarter, missing the consensus estimate of -$0.433 by -$0.427.

Is Jade Biosciences overvalued?

According to Wall Street analysts Jade Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Jade Biosciences pay dividends?

Jade Biosciences pays a Notavailable dividend of $2.4 which represents an annual dividend yield of 29.56%. See more information on Jade Biosciences dividends here

What is Jade Biosciences’s EPS estimate?

Jade Biosciences’s EPS estimate is -0.55.

How many shares outstanding does Jade Biosciences have?

Jade Biosciences has 32,626,730 shares outstanding.

What happened to Jade Biosciences’s price movement after its last earnings report?

Jade Biosciences reported an EPS of -$0.86 in its last earnings report, missing expectations of -$0.433. Following the earnings report the stock price went down -7.64%.

Which hedge fund is a major shareholder of Jade Biosciences?

Currently, no hedge funds are holding shares in JBIO

Jade Biosciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

-38.06%

Trailing 12-Months

Asset Growth

100.52%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Jade Biosciences

Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.

Jade Biosciences (JBIO) Earnings & Revenues

Historic Earnings Reports

JBIO Stock 12 Month Forecast

Average Price Target

$17.00

▲(110.92% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","32":"$32","59":"$59","86":"$86","113":"$113"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,32,59,86,113],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.89,7.7446153846153845,8.599230769230768,9.453846153846154,10.308461538461538,11.163076923076922,12.017692307692307,12.872307692307691,13.726923076923075,14.581538461538461,15.436153846153847,16.29076923076923,17.145384615384614,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.89,7.667692307692308,8.445384615384615,9.223076923076922,10.00076923076923,10.778461538461539,11.556153846153846,12.333846153846153,13.111538461538462,13.889230769230767,14.666923076923077,15.444615384615386,16.22230769230769,{"y":17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.89,7.59076923076923,8.291538461538462,8.992307692307692,9.693076923076923,10.393846153846154,11.094615384615384,11.795384615384615,12.496153846153845,13.196923076923076,13.897692307692306,14.598461538461537,15.299230769230768,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":112.44,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.2,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.81,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.22,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.54,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.2,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.69,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.88,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.18,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.2,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.89,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >